STATOpinion

For Intellia Therapeutics, CRISPR drug’s safety concern is an existential threat

Intellia Therapeutics will find it challenging to survive now that its CRISPR gene-editing treatment has been tied to severe, ...
STAT

Uncertainty in CRISPR world and the start of more M&A

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.
Benzinga.com

CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst

CRISPR Therapeutics AG (NASDAQ:CRSP) reported new topline study results on Wednesday to establish risk factors for atherosclerotic heart disease. The company disclosed data regarding the first 10 ...
MedCity News

CRISPR Biotech Caribou Trims Pipeline and Cuts 32% of Staff to Focus on Two Cancer Cell Therapies

Caribou Biosciences’ 2025 outlook aimed for key trial readouts for two cancer cell therapies in the first half of the year and the start of clinical testing in an autoimmune disease. The CRISPR ...
Seeking Alpha

CRISPR Therapeutics: Shares Are Soaring - This Could Be The Start Of Something Big

CRISPR Therapeutics AG stock has surged nearly 90% since my Buy call in early May, reaching its highest value since February 2024. The rally builds on the historic approval of Casgevy, a gene editing ...